Evidence map›Paper›PMID 32529352›Full record

ArticleCytotechnology2020

Investigation of the potential anticancer effects of napelline and talatisamine dirterpenes on experimental brain tumor models.

Merve Demirbağ Karaali, Elanur Aydın Karataş

Open access · greenAbstract read
In one paragraph

Article in Cytotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Targeting colon cancer via antimicrobial RT2 peptide: a system biology study.Gastroenterology and hepatology from bed to bench · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Merve Demirbağ KaraaliFaculty of Science, Department of Molecular Biology and Genetics, Erzurum Technical University, Erzurum, Turkey. mervedemirbagg@gmail.com.
Elanur Aydın KarataşFaculty of Science, Department of Molecular Biology and Genetics, Erzurum Technical University, Erzurum, Turkey.
Erzurum Technical University · TR

Funding

Erzurum Teknik Üniversitesi (TR) 2017/20
6 · The paper itself

Abstract

Brain cancers are one of the most aggressive tumours in humans. Especially, gliomas are among the deadliest of human cancers and show high resistance to chemotherapeutic agents. On the other hand, discovery of biologically effective non-synthetic biomaterials in treatments of different diseases, especially cancer, has continued to be one of the most popular research topics today. Therefore, we aimed to investigate biochemical, cytological and molecular genetic effects of napelline and talatisamine diterpenes in human U-87 MG glioma cells by using total antioxidant status and total oxidative status, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxphenyl)-2-(4-sulfophenyl)-2H-tetrozolium, inner salt and lactate dehydrogenase release assay and RT2 Prolifer PCR Arrays. Our results revealed that napelline and talatisamine exhibited cytotoxic effects at high doses. Napelline and talatisamine diterpenes increased apoptosis compared to control in U-87 MG cells. While napelline induced up-regulation of 50 and down-regulation of 13 genes, talatisamine induced up-regulation of 32 and down-regulation of 18 genes in U-87 MG cells. Napelline was shown to have a higher anticancer activity than talatisamine. We think that, napelline and talatisamine might be evaluated as potential chemotherapeutic agents for treatment of glioblastoma.

Indexed as

Anticancer activityApoptosizCytotoxicityDiterpenesGlioblastoma multiforme

Identifiers

PMID32529352
PMCPMC7450011
OpenAlexW3035242492

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.